MARKET

CPRX

CPRX

Catalyst Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.440
-0.260
-5.53%
After Hours: 4.430 -0.01 -0.23% 17:56 11/15 EST
OPEN
4.600
PREV CLOSE
4.700
HIGH
4.610
LOW
4.160
VOLUME
3.95M
TURNOVER
--
52 WEEK HIGH
7.67
52 WEEK LOW
1.850
MARKET CAP
457.50M
P/E (TTM)
51.57
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CPRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CPRX News

  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX
  • ACCESSWIRE.14h ago
  • Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.3d ago
  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX
  • ACCESSWIRE.3d ago
  • Catalyst Pharmaceuticals Inc (CPRX) Q3 2019 Earnings Call Transcript
  • MotleyFool.com.3d ago

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About CPRX

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
More

Webull offers Catalyst Pharmaceuticals Inc (CPRX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.